Clinical Cardiology Alert – July 1, 2017
July 1, 2017
View Issues
-
Late-breaking Clinical Trials from the Heart Rhythm Society May 2017 Scientific Sessions
Late-breaking findings of several important clinical trials were presented at this year’s Heart Rhythm Society Scientific Sessions in Chicago. A selection particularly relevant to the general cardiology community is presented here.
-
Antiplatelet Therapy After TAVR: More ARTE Than Science
The current clinical standard of dual antiplatelet therapy following transcatheter aortic valve replacement is controversial.
-
Distinguishing Ischemic From Non-ischemic Cardiomyopathy Clinically
The authors of a recent study concluded that specific clinical and ECG abnormalities could be used to estimate which patients with reduced left ventricular ejection fraction were at low risk of having ischemic cardiomyopathy.
-
B-type Natriuretic Peptide Is Less Useful in Elderly Patients With Dyspnea
Among patients ≥ 80 years of age presenting with acute dyspnea, B-type natriuretic peptide level was not useful for differentiating cardiac vs. respiratory etiologies when added to a model of clinical predictors.
-
Left Ventricular Volume Affects Function in Chemotherapy Patients
Reductions in left ventricular ejection fraction in patients receiving potentially cardiotoxic chemotherapy may be because of significant decreases in left ventricular volume in up to 20% of these patients.